Alleviation of fibrosis and oxidative stress in pressure overload-induced cardiac remodeling and heart failure via SIRT3 activation by colchicine

Heart failure (HF) is the end stage of many cardiovascular diseases, which is often associated with myocardial hypertrophy and cardiac remodeling. Among them, pressure overload-induced myocardial injury is one of the most common causes of heart failure. Colchicine, a drug widely used in the treatmen...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications Vol. 770; p. 151957
Main Authors: Wu, Mengze, Chen, Guodong, Peng, Yuce, Luo, Suxin
Format: Journal Article
Language:English
Published: United States Elsevier Inc 12.07.2025
Subjects:
agonists
Animals
atrial fibrillation
Colchicine
Colchicine - pharmacology
Colchicine - therapeutic use
coronary artery disease
drugs
fibroblasts
Fibroblasts - drug effects
Fibroblasts - metabolism
Fibroblasts - pathology
Fibrosis
Heart failure
Heart Failure - drug therapy
Heart Failure - metabolism
Heart Failure - pathology
hypertrophy
Male
Mice
Mice, Inbred C57BL
Myocardium - metabolism
Myocardium - pathology
Oxidative stress
Oxidative Stress - drug effects
risk reduction
simulation models
SIRT3
Sirtuin 3 - metabolism
therapeutics
Ventricular Remodeling - drug effects
Heart failure
Oxidative stress
Colchicine
Fibrosis
SIRT3
ISSN:0006-291X, 1090-2104, 1090-2104
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Heart failure (HF) is the end stage of many cardiovascular diseases, which is often associated with myocardial hypertrophy and cardiac remodeling. Among them, pressure overload-induced myocardial injury is one of the most common causes of heart failure. Colchicine, a drug widely used in the treatment of inflammatory diseases, has recently been found to significantly reduce the risk of cardiovascular events in patients with coronary artery disease and atrial fibrillation. However, the specific mechanism of colchicine has not been fully elucidated. We used the transverse aortic constriction (TAC) model to simulate cardiac pressure overload in mice. We found that colchicine attenuated TAC-induced heart failure and alleviated cardiac oxidative stress and fibrosis. To explore the specific molecular mechanism, we treated primary cardiac fibroblasts (CFs) and HL-1 with Ang Ⅱ in vitro to simulate the occurrence of TAC model. We found that colchicine induced SIRT3 activation and alleviated myocardial oxidative stress and cadiac fibrosis. Additionally, the SIRT3-selective agonist HKL exerts similar effects to colchicine, whereas the SIRT3-selective inhibitor 3-TYP partially reverses the therapeutic effects of colchicine. Our findings suggest that colchicine reduced cardiac oxidative stress and fibrosis by activating SIRT3, which in turn alleviated the progression of pressure overload-induced heart failure. Fig. 7. Graphical AbstractColchicine ameliorates TAC-induced myocardial injury and heart failure by activating SIRT3, which subsequently activates the NRF2/NQO1 antioxidant pathway and inhibits the α-SMA/TGF-β fibrotic pathway. Created in BioRender. Zhang, L. (2025) https://BioRender.com/ji7p2oo. [Display omitted] •Colchicine alleviates pressure overload-induced cardiac remodeling and heart failure.•Colchicine alleviates pressure overload-induced cardiac fibrosis.•Colchicine reduces pressure overload-induced myocardial oxidative stress.•Colchicine exerts a cardioprotective effect by activating SIRT3 pathway.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0006-291X
1090-2104
1090-2104
DOI:10.1016/j.bbrc.2025.151957